RenovoRx Inc. (NASDAQ:RNXT) Q2 2025 Earnings: Revenue Surpasses Estimates, Shares Climb on Positive Results

RenovoRx Inc. (NASDAQ:RNXT) Reports Q2 2025 Earnings: Revenue Beats Estimates, Shares Rise

RenovoRx Inc. (NASDAQ:RNXT) posted its second-quarter 2025 financial results, reporting revenue of $422,000, surpassing analyst estimates of $336,263. The company also reported a net loss per share of $0.08, slightly better than the anticipated loss of $0.0867. Following the earnings release, shares rose nearly 4.8% in after-hours trading, suggesting a positive market reaction to the results.

Key Financial Highlights

• Revenue Growth: The $422,000 in revenue marks the second full quarter of commercial sales for RenovoCath, the company’s FDA-cleared drug-delivery device. This represents a 25.5% beat over consensus estimates.
• Net Loss: The net loss widened to $2.9 million compared to $2.4 million in the prior-year quarter, primarily due to increased operating expenses and a $350,000 non-cash charge related to the fair value adjustment of warrant liabilities.
• Cash Position: The company ended the quarter with $12.3 million in cash, which management believes is sufficient to fund operations, including ongoing commercialization efforts and the Phase III TIGeR-PaC trial.

Commercial and Clinical Progress

RenovoRx highlighted continued momentum in its commercialization strategy, with 13 cancer centers now approved to purchase RenovoCath, up from five in the previous quarter. Four of these centers have already placed repeat orders, signaling early adoption. The company also appointed Philip Stocton as Senior Director of Sales and Market Development to expand its commercial footprint.

On the clinical front, the independent Data Monitoring Committee (DMC) for the Phase III TIGeR-PaC trial recommended continuing the study following a second interim analysis. While interim data was not disclosed to maintain trial integrity, management remains optimistic about enrollment completion later this year or early 2026.

Market Reaction and Outlook

The stock’s after-hours gain suggests investors were encouraged by the revenue beat and steady progress in commercialization. Analysts currently project full-year 2025 revenue at $1.38 million, with Q3 estimates at $514,080. The company did not provide formal guidance, but CEO Shaun Bagai emphasized a focus on scaling RenovoCath sales and advancing clinical trials.

For more detailed earnings estimates and future projections, visit RenovoRx’s earnings page.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research before making any financial decisions.